Skip to Content

Codexis Inc CDXS

Morningstar Rating
$3.15 −0.02 (0.63%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CDXS is trading within a range we consider fairly valued.
Price
$3.16
Fair Value
$6.27
Uncertainty
Extreme
1-Star Price
$56.80
5-Star Price
$6.89
Economic Moat
Hwrt
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CDXS is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$3.17
Day Range
$3.093.22
52-Week Range
$1.454.91
Bid/Ask
$2.90 / $3.46
Market Cap
$222.26 Mil
Volume/Avg
223,020 / 541,867

Key Statistics

Price/Earnings (Normalized)
Price/Sales
2.93
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
174

Comparables

Valuation

Metric
CDXS
VCYT
TIHE
Price/Earnings (Normalized)
25.00
Price/Book Value
2.801.47
Price/Sales
2.934.19
Price/Cash Flow
29.13
Price/Earnings
CDXS
VCYT
TIHE

Financial Strength

Metric
CDXS
VCYT
TIHE
Quick Ratio
3.434.41
Current Ratio
3.715.00
Interest Coverage
−11,324.57
Quick Ratio
CDXS
VCYT
TIHE

Profitability

Metric
CDXS
VCYT
TIHE
Return on Assets (Normalized)
−26.96%8.19%
Return on Equity (Normalized)
−45.98%8.76%
Return on Invested Capital (Normalized)
−37.18%7.87%
Return on Assets
CDXS
VCYT
TIHE
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRFgtnkwstQwry$593.7 Bil
VRTX
Vertex Pharmaceuticals IncVgjyfjpdXddbsd$115.3 Bil
REGN
Regeneron Pharmaceuticals IncVhsbsnsFwyynzk$107.2 Bil
MRNA
Moderna IncCxvshnvbjScd$58.7 Bil
BNTX
BioNTech SE ADRWcsrldtlmQrl$22.7 Bil
ARGX
argenx SE ADRZxmycpspGpbp$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncRvptszlpXtvgym$19.0 Bil
BMRN
Biomarin Pharmaceutical IncGrlrxkvZqzxpj$14.3 Bil
INCY
Incyte CorpTppyrfppmCxhwzyr$12.9 Bil
RPRX
Royalty Pharma PLC Class ALbqqjwffmcKmyxxv$12.0 Bil

Sponsor Center